MetaCap

Biomea Fusion (BMEA) vs Rallybio (RLYB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rallybio (RLYB) has outperformed Biomea Fusion (BMEA) over the past year, gaining 208.4% versus a loss of 41.5%. Over five years, RLYB leads with a -85.3% price change compared with -95.2% for BMEA. Rallybio is the larger company by market cap ($43.3 million vs $41.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMEA-41.51%RLYB+208.41%
+258%+96%-65%
Nov 21, 20251 yearNov 20, 2026
BMEA-94.67%RLYB-85.73%
+298%+91%-117%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMEA versus RLYB key metrics
MetricBMEARLYB
Share price$0.5744$15.47
Market cap$41.75M$43.32M
1-day change-2.38%-0.32%
YTD return-53.68%+181.89%
1-year return-41.51%+208.41%
5-year return-95.21%-85.29%
P/E ratio (TTM)—3.36
EPS (TTM)$-0.10$4.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$858.00K
Revenue growth (YoY)—+34.91%
Net income (latest FY)$-61.80M$-8.98M
Operating margin—-3853.61%
Net margin—-1046.39%
52-week high$2.24$35.15
52-week low$0.45$7.34
Distance from 52-week high-74.32%-55.99%
Analyst consensusbuy—
Avg. price target upside+1118.66%—
Average volume2.22M10.14K
Shares outstanding72.68M2.80M
Employees377
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLYB has outperformed BMEA by 249.9 percentage points over the past year.

About Biomea Fusion

BMEA stock →

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Rallybio

RLYB stock →

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

BMEA vs RLYB FAQ

Which is bigger, Biomea Fusion or Rallybio?

Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $41.75M for Biomea Fusion (BMEA).

Which stock has performed better over the past year, BMEA or RLYB?

RLYB returned +208.41% over the past 12 months, compared with -41.51% for BMEA (price return, excluding dividends). Past performance does not predict future results.

Are Biomea Fusion and Rallybio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons